AB569

April 28, 2016April 28, 2016

European Committee Releases Positive Opinion on Cystic Fibrosis Drug for Orphan Medicinal Product

Cystic Fibrosis, News

Canada-based biotech Arch Biopartners announced the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) has released a positive recommendation for the company’s treatment for infections linked to cystic fibrosis (CF). The ... Read more

April 6, 2016April 6, 2016

Arch Biopartners Licenses Drug Candidate to Treat CF Lung Infections

Cystic Fibrosis, News

Arch Biopartners, Inc., recently announced that it has entered an exclusive license agreement with the University of Cincinnati (UC) for commercial rights to UC’s AB569, a drug candidate for the ... Read more

February 5, 2016February 18, 2016

Respiratory Infections in CF Patients Are Focus of Orphan Drug Application in Europe

News

Arch Biopartners recently announced that it filed an application for orphan drug designation to the European Medicines Authority (EMA) for its medicine AB569, developed as a treatment for the bacterium Pseudomonas aeruginosa (P. aeruginosa) that ... Read more

November 17, 2015November 17, 2015

Arch Biopartners’ Cystic Fibrosis Therapy Given Orphan Drug Designation

Cystic Fibrosis, News

Arch Biopartners Inc., a biotechnology company focused on the development of new technologies with clinical relevance, has announced that its investigational drug AB569 has been granted Orphan Drug Designation by the U.S. Food ... Read more

September 18, 2015November 5, 2015

Arch Biopartners New Therapy Could Treat Infections With Resistant P. Aeruginosa in CF Patients

Cystic Fibrosis, News

On September 17th, 2015, Arch Biopartners Inc. announced that the drug AB569 designed to treat pulmonary infections with Pseudomonas aeruginosa (P. aeruginosa) completed successful pre-clinical in vitro and in vivo ... Read more